Actuate therapeutics highlights significant and sustained survival benefit in key metastatic pancreatic cancer patient populations in phase 2 elraglusib trial

- near doubling of 1-year overall survival (os), increased median os of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (gnp) vs gnp alone

ACTU Ratings Summary

ACTU Quant Ranking